Shares of the cancer specialist Puma Biotechnology, Inc. (NASDAQ: PBYI) are getting blasted in after-hours trading today following the release of the company's third-quarter earnings report. Specifically, the stock dropped by more than 37% in extended trading today.
What's causing investors to hit the exits? While Puma's breast cancer drug Nerlynx raked in $52.6 million for the three-month period, the drug's commercial momentum appears to be slowing. Quarter over quarter, Nerlynx's sales only rose by 3.5%, after all.
Wall Street has been growing increasingly weary of Nerlynx's lack of commercial momentum, and these latest numbers appear to justify that reaction. While most cancer drugs -- especially those indicated for a form of breast cancer -- generally show exceptionally strong sales trajectories for several years after launch, Nerlynx's sales are clearly starting to flatten out only a little over a year after the drug's debut.
Is this 37% drop in Puma's share price justified? The good news for shareholders is that this sell-off is probably way overdone. Nerlynx's sales, after all, are widely expected to pick up as the drug's international footprint expands. In fact, Puma's shares were only trading at a forward-looking (2019) price-to-sales ratio of 4.3 prior to this downturn. That's a rock-bottom valuation for a cancer drug company.
The take-home point is that Wall Street seems to be overreacting to Puma's third-quarter report. Bargain hunters, therefore, might want to consider picking up some shares of this promising biotech, especially if this marked sell-off holds into tomorrow's session.
10 stocks we like better than Puma Biotechnology
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Puma Biotechnology wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.